About us

• Mission and strategy
• Organisation
  • Governance Board
  • Steering Committee
  • Council of Trustees
  • Operational Office
  • Product development team
  • Clinical development team
• Our partners
• Financials
• Registration and documents
• Downloads
• Contact

1. TBVI »
2. About us »
3. Organisation »
4. Product development team »
5. Dr. Barry Walker

Dr. Barry Walker is a Principal Scientist in the Biotherapeutics Group at the National Institute for Biological Standards and Control (a centre of the Health Protection Authority) and is the lead scientist in the Immunology and Cellular Immunity Section and has maintained a research interest in tuberculosis and the immunology of vaccines against poverty related diseases, including HIV and Malaria. Dr. Walker trained at the University of Western Australia, and completed his PhD in the immunology of renal transplantation. Subsequently he moved to the UK, to the Royal Postgraduate Medical School, where his interest in mycobacterial infection and vaccinology was fostered. After a period at the National Institute for Medical Research at Mill Hill, he moved to his current position at NIBSC where has continued his involvement in tuberculosis, HIV and malaria.

Dr. Walker is one of the core members of Product Development Team (PDT) within the new TB Vaccine Consortium (and in earlier FP5 and FP6 programmes) and provides regulatory advice and recommendations on vaccine safety, quality and characterisation to vaccine developers and manufacturers. Dr. Walker is work-package leader for Work-package 7, containing the operations of the PDT and its role in facilitating the preclinical development programme within the NEWTBVAC consortium.